Protagenic Therapeutics Cash Flow Conversion Efficiency
Protagenic Therapeutics cash flow conversion efficiency. Based on the latest financial reports, Protagenic Therapeutics (PTIX) has a cash flow conversion efficiency ratio of 0.087x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-410.42K) by net assets ($-4.69 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Protagenic Therapeutics (1995–2025)
Cash flow conversion efficiency of Protagenic Therapeutics from 1995 to 2025. This chart illustrates how Protagenic Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Protagenic Therapeutics stock price today for real-time trading data and today's change.
Protagenic Therapeutics Cash Flow Conversion Ratio Explained
Protagenic Therapeutics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Protagenic Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Protagenic Therapeutics ranked by their cash flow conversion efficiency. Also see how much is Protagenic Therapeutics worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Cho Thavee Public Company Limited
BK:CHO
|
-0.006x |
|
Reneuco Berhad
KLSE:7130
|
0.013x |
|
Goldex Resources Corp
V:GDX
|
0.000x |
|
Castings PLC
LSE:CGS
|
0.124x |
|
CardioComm Solutions Inc.
V:EKG
|
0.215x |
|
Niraj Ispat Industries Limited
NSE:NIRAJISPAT
|
0.006x |
|
Ausmon Resources Ltd
AU:AOA
|
-0.232x |
|
Moab Minerals Ltd
AU:MOM
|
-0.120x |
Annual Cash Flow Conversion Efficiency for Protagenic Therapeutics (1995–2025)
The table below shows the annual cash flow conversion efficiency of Protagenic Therapeutics from 1995 to 2025. Review Protagenic Therapeutics (PTIX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-4.69 Million | $-4.14 Million | 0.882x | +121.20% |
| 2024-12-31 | $1.01 Million | $-4.22 Million | -4.162x | -312.17% |
| 2023-12-31 | $3.67 Million | $-3.70 Million | -1.010x | -250.32% |
| 2022-12-31 | $6.92 Million | $-1.99 Million | -0.288x | -2.39% |
| 2021-12-31 | $9.94 Million | $-2.80 Million | -0.281x | -124.00% |
| 2020-12-31 | $-1.15 Million | $-1.35 Million | 1.173x | +52.50% |
| 2019-12-31 | $-634.37K | $-487.99K | 0.769x | -84.86% |
| 2018-12-31 | $-210.88K | $-1.07 Million | 5.080x | +548.78% |
| 2017-12-31 | $1.22 Million | $-1.38 Million | -1.132x | -145.87% |
| 2016-12-31 | $2.48 Million | $-1.14 Million | -0.460x | -169.54% |
| 2015-12-31 | $-571.00K | $-378.00K | 0.662x | -12.96% |
| 2015-06-30 | $-497.00K | $-378.00K | 0.761x | -93.26% |
| 2014-12-31 | $-70.00K | $-790.00K | 11.286x | 0.00% |
| 2013-12-31 | $-70.00K | $-790.00K | 11.286x | +59902.38% |
| 2012-12-31 | $-17.23 Million | $-324.00K | 0.019x | +101.37% |
| 2010-12-31 | $8.17 Million | $-11.25 Million | -1.377x | -1057.35% |
| 2009-12-31 | $25.35 Million | $-3.02 Million | -0.119x | -249.26% |
| 2008-12-31 | $54.65 Million | $4.36 Million | 0.080x | +125.80% |
| 2007-12-31 | $16.86 Million | $-5.21 Million | -0.309x | -140.58% |
| 2006-12-31 | $1.22 Million | $931.00K | 0.761x | +347.54% |
| 2004-12-31 | $2.74 Million | $-842.00K | -0.308x | -181.90% |
| 2003-12-31 | $4.98 Million | $1.87 Million | 0.376x | +106.06% |
| 2002-12-31 | $12.87 Million | $2.35 Million | 0.182x | +64.37% |
| 2001-12-31 | $13.57 Million | $1.50 Million | 0.111x | -56.20% |
| 2000-12-31 | $13.86 Million | $3.51 Million | 0.253x | +915.01% |
| 1999-12-31 | $13.27 Million | $331.00K | 0.025x | +180.14% |
| 1998-12-31 | $13.95 Million | $-434.00K | -0.031x | +81.20% |
| 1997-12-31 | $13.30 Million | $-2.20 Million | -0.166x | -406.58% |
| 1996-12-31 | $7.04 Million | $-230.00K | -0.033x | +59.11% |
| 1995-12-31 | $7.51 Million | $-600.00K | -0.080x | -- |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.